Swedish study indicates decline of neutralizing antibodies to mpox virus during the first month after vaccination

New research to be presented at this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) in Barcelona, Spain (27–30 April) shows that even in men who receive two doses of mpox vaccine intradermally, their level of antibodies to the virus falls to low or zero within the first few months if they have not received a previous smallpox vaccine.

Powered by WPeMatico

Spotting the signs of disordered eating in youth: Tips for parents and caregivers

In the age of social media, youth are constantly bombarded with viral trends and toxic messages that set unrealistic standards about the ideal body image. This has translated into a far too common expression of body shape dissatisfaction in young people.

Powered by WPeMatico

What is sugar and what would happen if I stopped eating it? A scientist explains

The world has declared a time-out on sugar consumption. The harmful link between disease and dietary sugar was recently outlined in a comprehensive assessment of published studies.

Powered by WPeMatico

Why women’s rugby needs its own injury prevention strategy

With the Women’s Six Nation’s Championship underway, there is mounting public concern regarding the risk of injuries to players.

Powered by WPeMatico

Klebsiella pneumoniae: An opportunistic pathogen harmless to some, but causes severe disease in others

Klebsiella pneumoniae is a common species of bacteria found in our bodies—and may even be lurking in your gut, mouth or nose right now. But it’s also a notoriously harmful bacteria that can make us very ill.

Powered by WPeMatico

Debunking Myths about avoiding Carbohydrates in Diabetes – Dr Arindam Pande

Diabetes is a chronic condition characterized by elevated blood sugar levels due to insufficient insulin production or ineffective insulin utilization. It’s concerning because uncontrolled diabetes can lead to various complications, including heart disease, kidney damage, nerve damage, vision loss, and an increased risk of infections. Managing diabetes is crucial to prevent these serious health issues and maintain overall well-being.

Contrary to the popular myth, not all carbohydrates need to be avoided in diabetes. While it’s important to regulate carbohydrate intake to manage blood sugar levels, not all carbs are created equal. Healthier carbohydrate sources such as whole grains, fruits, vegetables, and legumes provide essential nutrients, fiber, and energy without causing rapid spikes in blood sugar. It’s more about making smart carbohydrate choices and controlling portion sizes rather than completely eliminating all carbs. A balanced diet, combined with regular physical activity and medication as prescribed, can help individuals with diabetes effectively manage their condition while still enjoying a varied and nutritious diet.

In this video, Dr Arindam Pande discusses Diabetes and the complications related to it while addressing the misconception that all carbohydrates should be avoided in diabetes.

Powered by WPeMatico

Deficiency in Service: Consumer Court orders Aakash Institute to refund fee to NEET aspirant

Hyderabad: The District Consumer Disputes Redressal Commission (DCDRC), Hyderabad, recently directed Aakash Institute in Himayathnagar to pay Rs 68,353 as refund to a NEET aspirant for repeatedly demanding the course fee from the student and abruptly ceasing her access to the classes even though the payment was already made.

As per the complainant, she wanted to join the Olympiad Integrated Course in the Aakash Institute at Himayatnagar. Her father paid Rs 43,358 as the course fee through UPI. On 29.06.2022 he requested to change the track of the student from CBSE to ICSE the required details were shared through WhatsApp (no change of fee).

Initially, the officials at the institute had assured that the track would be changed to ICSE within 3-4 days. Accordingly, the student stopped attending the CBSE track classes as she was expecting to join ICSE track batch. However, there was no update.

Despite lodging multiple complaints, no solution was offered either by the Customer Care team or the administration. Finally, the student got the study material after four months on 27.10.2022.

However, shockingly, the access was cut off by the institute alleging that the tuition fee was due. After the matter was pursued by the student’s father, an official from the institute intervened and restored the access on 03.12.2022.

Also Read: Kota Coaching Centres told to halt routine tests of NEET aspirants

Once again the access was discontinued while the student’s father received multiple messages showing different amounts of dues. Even though the student’s father reached out to the Institute administration multiple times, it stopped responding to him. 

It was alleged that the student’s father ran from pillar to post to resolve the issue and had even attempted to talk to customer care/support and management but to no avail.

Claiming that the complainant and her father had been put through severe mental, and physical agony, distress and trauma due to the deficiency of the institute and also claiming that the disruption in the course hampered the complainant’s education and disturbed her career goals, the complainant demanded a refund of the entire course fee i.e. Rs 43,338 with interest and another Rs 5 lakh for mental agony. 

On the other hand, the institute denied all complaints and submitted that the complainant got admitted based on the Terms and Conditions of the Admission Form and Refund Policy. They further claimed that the customer care officers are very quick and prudent in replying and solving the problems raised. Therefore, the complainant is not entitled to the relief claimed. 

Opining that there was deficiency in service, the consumer court held that the institute was liable to refund the fee of Rs.43,358 along with interest @ 12% p.a., from 03.12.2022 and also pay compensation of Rs.10,000. Further, the Commission ordered the Institute to pay Rs 10,000 to consumer legal laid account towards punitive damages and also pay costs of Rs 5,000.

Commenting on the matter, the student’s father told The New Indian Express, “Even though it is a reputed institute, the employees showed inefficiency. More than the money, I was concerned about my daughter losing a year of preparation due to this delay. We lost an advantage of a year due to this.”

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/neet-aspirant-vs-aakash-institute-235085.pdf

Also Read: NEET aspirants below 16 years will not be allowed to join coaching centres

Powered by WPeMatico

JIPMER Invites Application for Research Proposals To IEC Observational Studies April 2024

Puducherry- The Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, has issued a circular inviting online applications for the submission of proposals to the Institutional Ethics Committee Observational Studies for the April 2024 session.

The last date for submission of proposals by faculty, PhD scholars, P.G. and U.G. Students to reach the office of the undersigned for consideration of approval by the Institutional Ethics Committee for April 2024 is on or before Tuesday, April 02, 2024. The proposals submitted before the last date will be taken up for discussion in the IEC Observational Committee meeting which will be held on Thursday, April 11, 2024.

Also Read: JIPMER invites applications for Research Proposals To IEC Interventional Studies For April 2024, Details

Candidates must submit one hard copy of certain documents to the Member-Secretary at the Institute Ethics Committee (IEC) office, Room no. 106, First floor, Administrative block, JIPMER.

DOCUMENTS

1 Covering letter.

2 Download of the online IEC application.

3 Signed Declaration form.

4 Consent forms / Waiver of consent forms.

5 Research proposal JSAC (ver. July 2020) / UGRMC/PGRMC.

6 JSAC/ UGRMC/PGRMC certificate.

7 Data collection proformas.

8 Curriculum vitae of PI & Co-Investigator (s) / guide & co-guide.

Also Read: JIPMER invites applications for Research Proposals To IEC Interventional Studies For February 2024, Details

As per the notice, states, “Faculty, PhD scholar, P.G. and U.G. Students are invited to submit research proposals approved by JSAC/PGRMC/SCTRC/GJ-STRAUS for approval by Institutional Ethics Committee – Observational studies in the prescribed proforma”.

PIs are instructed to upload their signed declaration form, consent form and soft copy of the scientific proposal through the mentioned link, the notice lastly stated.

The Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER) is a medical school in Pondicherry. It is an institute of national importance (INI) and a tertiary care referral hospital. It is under the direct administrative control of the Ministry of Health and Family Welfare and the Indian Government, with autonomy to run its internal administration. The courses include undergraduate, postgraduate, super speciality, fellowships, PhD programs, post-basic diplomas, and certified courses.

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/iec-os-call-for-proposal-april-235135.pdf

Powered by WPeMatico

VIP Convoy: No Doctor in Ambulance accompanying MP Governor, Protocol Officer Suspended

Indore: A protocol officer from the Madhya Pradesh Health Department has been suspended following the discovery that no doctor was designated for duty in the ambulance accompanying the convoy of Karnataka Governor Thawarchand Gehlot. The incident came to light when Gehlot’s granddaughter fell ill while traveling through Indore district, prompting swift action and raising concerns over the adequacy of medical arrangements.

“The Karnataka Governor’s granddaughter, who was with him in the convoy, fell ill near Indore on Friday evening. But there was no doctor in the ambulance,” Collector Ashish Singh told PTI.

Also Read:Wrong blood transfused at Rajkot Hospital, Resident doctor suspended

Subsequently, Gehlot’s granddaughter was admitted to a private hospital, where she received necessary medical care and is reported to be in stable condition. However, the incident led to disciplinary action against the responsible protocol officer.

“The protocol officer of the health department has been suspended for negligence in putting in place appropriate medical arrangements in the governor’s motorcade,” Indore’s Chief Medical and Health Officer Dr B S Saitya said.

“It was the duty of this protocol officer to mark a doctor on duty in the ambulance attached to the convoy of the important and very important persons,” he added.

Also Read:Dereliction of Duty: Medical Officer faces suspension, another under radar of JnK Health Dept

Powered by WPeMatico

Gilead Sciences gets exclusive global license to develop, commercialize Xilio tumor-activated IL-12

Foster City: Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies. The company is using its proprietary tumor-activation platform to build a pipeline of novel, tumor-activated molecules, including antibodies, cytokines, bispecifics, and cell engagers, which are designed to optimize the therapeutic index and localize anti-tumor activity within the tumor microenvironment. XTX301 is currently being evaluated in a Phase 1 dose escalation trial in patients with advanced solid tumors.

“Xilio’s novel tumor-activation platform naturally complements Gilead’s clinical development program in difficult-to-treat cancers and expands our focus in immuno-oncology,” said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Development, Gilead Sciences. “We believe IL-12 has the potential to treat a broad range of tumor types and are excited to partner with Xilio to advance XTX301, a tumor-activated IL-12, as a monotherapy and a combination therapy across a variety of solid tumors.”

“Gilead’s confidence in our tumor-activated technology, combined with their deep expertise in developing and commercializing novel immuno-oncology products, will enable us to accelerate and expand the development of XTX301, our tumor-activated IL-12,” said René Russo, Pharm.D., President and Chief Executive Officer of Xilio. “We look forward to collaborating with Gilead as we seek to deliver on the potential for XTX301 to provide a meaningful benefit for a range of tumor types, including immunologically cold tumors, while overcoming the severe toxicities historically associated with IL-12.”

Under the terms of the agreement, Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio’s tumor-activated IL-12. Xilio will receive $43.5 million in upfront payments, including a cash payment of $30 million and an initial equity investment by Gilead of $13.5 million in Xilio common stock at a premium. Xilio will be eligible to receive up to $604 million in additional contingent payments, including additional equity investments by Gilead, a transition fee and specified development, regulatory and sales-based milestones. Xilio will also be eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales.

Xilio will be responsible for conducting clinical development of XTX301 in the ongoing Phase 1 clinical trial through dose expansion. Following the delivery by Xilio of a specified clinical data package for XTX301, Gilead can elect to transition responsibilities for the development and commercialization of XTX301 to Gilead, subject to the terms of the agreement and payment by Gilead of a $75 million transition fee. Prior to the potential transition fee, Xilio is eligible to receive up to a total of $29 million in additional equity investments and a development milestone payment.

Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction is expected to reduce Gilead’s GAAP and non-GAAP 2024 EPS by approximately $0.03 – $0.04.

Read also: Gilead Sciences completes acquisition of CymaBay Therapeutics for USD 4.3 billion

Powered by WPeMatico